secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125336
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio Q3 net loss $8.9M; cash $217.9M through 2027; FDA IND cleared for SLE trial
--------------------------------------------------------------------------------

- Net loss $8.9M for Q3 2024 vs $4.0M Q3 2023; R&D expenses $6.2M, G&A $5.5M.
- Cash $217.9M as of Sep 30, 2024; expected to fund operations through 2027.
- FDA cleared IND for budoprutug in SLE; Phase 1b trial planned H1 2025.
- Appointed Doug Williams as Chair of Board; Gary Hao as VP of CMC.
- Phase 1b pMN data showed 60% complete remission; Phase 2 ITP trial planned H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017024125336/0000950170-24-125336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017024125336/clym-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer